Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use

Abstract

The addition of the MBDA test to clinical assessment led to meaningful changes in the treatment plans of 38% of RA patients being cared for by HCPs in office practice. Even though treatment was potentially improved, the overall quantity of drug use was minimally affected.